Updated 01 February 2017

Diabetes medication shows osteoporosis link

The popular diabetes drug marketed as Avandia may increase bone thinning, a discovery that could help explain why diabetics can have an increased risk of fractures.


New research raises the possibility that long-term diabetes treatment with rosiglitazone, as Avandia is also called, could lead to osteoporosis.

The diabetes drug is used to improve response to insulin.

While bones seem solid, they constantly are being broken down and rebuilt by the body. Researchers found that in mice, the drug increased the activity of the cells that degrade bones, according to a report in this week's online issue of Nature Medicine.

Heart failure warning

Avandia recently was labelled with warnings about the risk of heart failure in some patients. GlaxoSmithKline, which markets the drug, already has acknowledged that a study found a higher risk of fractures among women who take the drug. But this report is the first to attempt to explain the link between the drug and fractures.

The finding "has led to a better understanding of the challenges associated with long-term treatment of patients with Type II diabetes," said Ronald M. Evans of the Salk Institute for Biological Studies in La Jolla, California, lead author of the report.

"It also provides a basis for the development of a 'next generation' of drug that can specifically dial out this side effect and a new insight into a previously unrecognised aspect of bone physiology that has important medical consequences," he said in an interview via e-mail.

Nearly 21 million people in the United States have diabetes.

Rosiglitazone is widely used in people with Type II, or adult onset diabetes, the most common form of the disease.

Should be used by frail patients
Evans said the discovery was fortuitous. Researchers were looking at different aspects of the diabetic mice and did not realise they would be able to change the bone-removing activity.

The assumption had been that more brittle bones in diabetics were the result of a reduced bone-building activity, not increased bone removal.

"Considering the widespread use of these drugs and the known action in people it is surprising that such a key observation had been missed," he said.

"The long-term use of rosiglitazone should be cautious in patients with higher risk of fractures such as older women," he added. Using it in combination with anti-osteoporosis drugs could be beneficial, he said. – (Randolph E. Schmid/Sapa/AP)

Read more:
More Avandia concerns
Diabetes pill may be deadly

December 2007


Read Health24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Ask the Expert

Diabetes expert

Dr. May currently works as a fulltime endocrinologist and has been in private practice since 2004. He has a variety of interests, predominantly obesity and diabetes, but also sees patients with osteoporosis, thyroid disorders, men's health disorders, pituitary and adrenal disorders, polycystic ovaries, and disorders of growth. He is a leading member of several obesity and diabetes societies and runs a trial centre for new drugs.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules